Haemonetics Co. (NYSE:HAE) CEO Christopher Simon Sells 50,869 Shares

Haemonetics Co. (NYSE:HAE) CEO Christopher Simon sold 50,869 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $137.43, for a total transaction of $6,990,926.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Christopher Simon also recently made the following trade(s):

  • On Monday, July 1st, Christopher Simon sold 5,008 shares of Haemonetics stock. The shares were sold at an average price of $121.79, for a total transaction of $609,924.32.
  • On Wednesday, June 12th, Christopher Simon sold 1,248 shares of Haemonetics stock. The shares were sold at an average price of $109.37, for a total transaction of $136,493.76.
  • On Friday, June 7th, Christopher Simon sold 2,834 shares of Haemonetics stock. The shares were sold at an average price of $103.38, for a total transaction of $292,978.92.
  • On Thursday, May 23rd, Christopher Simon sold 24,412 shares of Haemonetics stock. The shares were sold at an average price of $99.39, for a total transaction of $2,426,308.68.

NYSE:HAE traded down $1.45 during trading hours on Thursday, reaching $133.89. 2,484 shares of the company’s stock were exchanged, compared to its average volume of 370,539. The firm has a market capitalization of $6.93 billion, a price-to-earnings ratio of 56.55, a P/E/G ratio of 3.34 and a beta of 0.82. The company has a 50-day moving average of $126.16 and a 200 day moving average of $102.31. The company has a quick ratio of 1.34, a current ratio of 2.10 and a debt-to-equity ratio of 0.54. Haemonetics Co. has a 1-year low of $80.24 and a 1-year high of $140.36.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.18. The firm had revenue of $238.50 million during the quarter, compared to analysts’ expectations of $236.82 million. Haemonetics had a net margin of 5.05% and a return on equity of 21.07%. Haemonetics’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.59 EPS. Research analysts forecast that Haemonetics Co. will post 3.03 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of HAE. Geode Capital Management LLC increased its holdings in Haemonetics by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 628,695 shares of the medical instruments supplier’s stock valued at $62,900,000 after purchasing an additional 27,344 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in Haemonetics during the 1st quarter valued at about $203,000. Virtu Financial LLC purchased a new position in Haemonetics during the 1st quarter valued at about $396,000. Ellis Investment Partners LLC purchased a new position in Haemonetics during the 1st quarter valued at about $79,000. Finally, BNP Paribas Arbitrage SA increased its holdings in Haemonetics by 1,162.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 11,069 shares of the medical instruments supplier’s stock valued at $968,000 after purchasing an additional 10,192 shares during the period. Hedge funds and other institutional investors own 99.23% of the company’s stock.

Several research analysts have recently issued reports on HAE shares. Raymond James upped their target price on shares of Haemonetics from $110.00 to $150.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th. Jefferies Financial Group upped their target price on shares of Haemonetics from $125.00 to $140.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Barrington Research restated an “outperform” rating and issued a $139.00 target price (up previously from $116.00) on shares of Haemonetics in a report on Wednesday, August 7th. TheStreet upgraded shares of Haemonetics from a “c+” rating to a “b-” rating in a report on Tuesday, May 7th. Finally, JMP Securities upped their target price on shares of Haemonetics to $145.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $140.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Read More: How does a reverse stock split work?

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.